These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 21463116

  • 1. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
    Tallman MS.
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():65-8. PubMed ID: 21463116
    [Abstract] [Full Text] [Related]

  • 2. Cladribine in hairy cell leukemia.
    Belani R, Saven A.
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
    [Abstract] [Full Text] [Related]

  • 3. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M, Machaczka M, Załuska A, Skotnicki AB.
    Przegl Lek; 1998 Oct; 55(7-8):400-6. PubMed ID: 10021885
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
    Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ.
    J Clin Oncol; 2020 May 10; 38(14):1527-1538. PubMed ID: 32109194
    [Abstract] [Full Text] [Related]

  • 6. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC.
    Clin Cancer Res; 1999 Jul 10; 5(7):1665-70. PubMed ID: 10430066
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Chemo-immunotherapy for hairy cell leukemia.
    Ravandi F.
    Leuk Lymphoma; 2011 Jun 10; 52 Suppl 2(0 2):72-4. PubMed ID: 21417822
    [Abstract] [Full Text] [Related]

  • 9. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
    Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, Baur A, Kurrer M, Von Rohr A, Hsu-Schmitz SF, Wagner B, Delacretaz F, Hurwitz N, Swiss Group for Clinical Cancer Research (SAKK).
    Arch Pathol Lab Med; 2006 Mar 10; 130(3):374-7. PubMed ID: 16519567
    [Abstract] [Full Text] [Related]

  • 10. Immunoconjugates in the management of hairy cell leukemia.
    Kreitman RJ, Pastan I.
    Best Pract Res Clin Haematol; 2015 Dec 10; 28(4):236-45. PubMed ID: 26614902
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O, Tomová A, Kusenda J, Gyárfás J.
    Neoplasma; 2001 Dec 10; 48(5):350-7. PubMed ID: 11845978
    [Abstract] [Full Text] [Related]

  • 14. Development of cladribine at Scripps for hairy cell leukemia and current results.
    Torrey ML, Sigal DS, Saven A.
    Leuk Lymphoma; 2011 Jun 10; 52 Suppl 2():29-33. PubMed ID: 21504293
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. My treatment approach to hairy cell leukemia.
    Naik RR, Saven A.
    Mayo Clin Proc; 2012 Jan 10; 87(1):67-76. PubMed ID: 22212971
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
    Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P.
    Leukemia; 1994 Jul 10; 8(7):1153-6. PubMed ID: 7913513
    [Abstract] [Full Text] [Related]

  • 20. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
    Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, Petrini M.
    Eur J Haematol; 2004 Dec 10; 73(6):412-7. PubMed ID: 15522063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.